Mark Foundation Invests $12 Million in Innovative Cancer Research Initiatives

Transformative Cancer Research with the Endeavor Awards

On October 7, 2026, the Mark Foundation for Cancer Research announced a groundbreaking investment of $12 million, aimed at supporting collaborative cancer research across borders. This funding, directed at four distinguished multi-institutional teams, enhances the Endeavor Awards portfolio that now totals over $50 million in grants since the program’s inception in 2021. With a mission to connect leading minds in the fight against cancer, this initiative prioritizes innovative and multidisciplinary approaches crucial for tackling the complex challenges presented by the disease.

Bridging International Gaps in Cancer Research

Amid ongoing uncertainties regarding research funding, The Mark Foundation recognizes the importance of fostering international scientific collaboration. By uniting diverse teams equipped with a range of unique expertise and technologies, this initiative encourages out-of-the-box thinking essential for developing effective cancer treatments. Four selected projects, funded with three-year grants of $3 million each, exemplify this cross-disciplinary approach, focusing on different aspects of cancer biology and treatment strategies.

1. Targeting Liver Metastasis
Led by researchers Sarah-Maria Fendt, Colinda Scheele, and Peter Siegel, this project explores the complex dynamics of liver metastasis, which affects approximately 2.5 million cancer patients annually. The team employs advanced mouse models that reflect tumor behavior in cancer patients, focusing on understanding how local liver conditions encourage aggressive tumor forms. By mapping interactions between cancer cells and healthy liver cells, they aim to identify vulnerabilities for personalized treatment strategies that could change patient outcomes dramatically.

2. Disrupting Immunotherapy Resistance in Gastric Cancer
Researchers Brent Hanks, Jenny Ting, and Elizabeth Brunk hypothesize that the cellular signaling pathways that tumor cells employ may be a key reason behind the failure of standard immunotherapy treatments. Their compelling findings indicate the NLRP3 pathway plays a critical role in preventing tumor recognition by the immune system. By utilizing specialized 3D tumor models constructed from patients' cells, the team investigates novel therapeutic drugs that can counteract these tumor defenses, facilitating immune cell access to eradicate malignancies.

3. Reprogramming Cancer-Associated Macrophages
An international collaboration led by Miriam Merad and others focuses on reversing macrophage corruption in the tumor microenvironment. These immune cells, intended to combat tumors, often morph into protectors of cancer cells. By understanding the two-step corruption process, the team strives to develop therapeutics capable of returning these immune cells to a cancer-fighting state.

4. Targeting Undruggable Drivers of Cancer
The BOLTS project, led by Georg Winter and his partners, aims to address the challenges posed by transcription factors—the master regulators of tumor cell proliferation that have been previously deemed undruggable. By leveraging groundbreaking insights from previous cancer treatments, this team looks to design drugs that effectively lock these factors into a state that halts tumor growth.

A Commitment to Innovative Science and Collaboration

The Mark Foundation's Endeavor Awards not only provide critical funding but also fundamentally alter the landscape of cancer research. By supporting high-risk projects developed through international collaboration, it ensures that scientists have the resources needed to challenge conventional methodologies and pursue innovative treatments.

Conclusion

In summary, the Mark Foundation for Cancer Research exemplifies how strategic funding and a commitment to collaboration can advance the fight against cancer. As the selected teams embark on their respective projects, the global scientific community watches, hopeful for breakthroughs that could shift the paradigm of cancer treatment.

With a history of impactful investments, the foundation continues to fuel innovations that promise new avenues for effective prevention, diagnosis, and treatment of cancer, contributing significantly toward the goal of ending cancer globally.